Clinical Trial Update: A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Participants With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the long-term safety of Ivacaftor in cystic fibrosis patients who started treatment before 24 months of age with Ivacaftor-responsive m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Kalydeco (Ivacaftor) (Ivacaftor)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 3 | Status: COMPLETED | Results posted: 2024-10-23